Entry Detail

General Information

Database ID: LDA0000646
Species: Homo sapiens
Confidence Score: 0.731059
Contents: >> ncRNA Information
>> ncRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference
Causality: Yes
Clinical Significance: Yes

 


ncRNA Information

Reference Genome Note: GRCh38 for human lncRNAs; GRCm39 for mouse lncRNAs; mRatBN7.2 for rat lncRNAs; hg19 for human circRNAs; mm9 for mouse circRNAs.

ncRNA Symbol:FOXP4‑AS1
Full Name:N/A
Category:LncRNA
Species:Homo sapiens
Synonyms:N/A
Chromosome:N/A
Strand:N/A
Coordinate:
Start Site(bp):0End Site(bp):0
External Links:
Ensembl ID:N/A
Ensembl Transcript ID:N/A
Entrez Gene:N/A
NONCODE ID:N/A
RefSeq Accession:N/A

 

ncRNA Association Statistics

Total Associated Disease Number:2   
More Information
Causal Disease Number:2
Network:
Top Causal Diseases:
Lymphoma, Mantle-Cell  (Score: 0.731059)
Lymphoma, Mantle-Cell  (Score: 0.731059)
More Information

 

 

Disease Information

 Disease OntologyMeSH
Disease ID:DOID:0050746D020522
Disease Name:mantle cell lymphomaLymphoma, Mantle-Cell
Category:Disease OntologyMeSH
Type:Neoplasms
Define:A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
Alias:Lymphoma, Mantle-Cell//Lymphoma, Mantle Cell//Lymphomas, Mantle-Cell//Mantle-Cell Lymphomas//Lymphocytic Lymphoma, Diffuse, Poorly Differentiated//Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated//Mantle-Zone Lymphoma//Lymphoma, Mantle-Zone//Lymphomas, Mantle-Zone//Mantle Zone Lymphoma//Mantle-Zone Lymphomas//Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated//Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated//Lymphoma, Small-Cell, Centrocytic//Mantle-Cell Lymphoma//Mantle Cell Lymphoma//Diffuse Lymphocytic Lymphoma, Poorly-Differentiated//Diffuse Lymphocytic Lymphoma, Poorly Differentiated//Lymphoma, Centrocytic Small-Cell//Centrocytic Small-Cell Lymphoma//Centrocytic Small-Cell Lymphomas//Lymphoma, Centrocytic Small Cell//Lymphomas, Centrocytic Small-Cell//Small-Cell Lymphoma, Centrocytic//Small-Cell Lymphomas, Centrocytic//Lymphoma, Lymphocytic, Intermediate

 

Disease Association Statistics

Total Associated ncRNA Number:16   
More Information
Causal ncRNA Number:16
Network:
Top Causal ncRNAs:
FOXP4‑AS1  (Score: 0.731059)
FOXP4-AS1  (Score: 0.731059)
GATA6-AS  (Score: 0.731059)
MANCR  (Score: 0.731059)
LINC01139  (Score: 0.731059)
circCTNNA1  (Score: 0.731059)
circCDYL  (Score: 0.731059)
ZNF667-AS1  (Score: 0.731059)
FOXP4‑AS1  (Score: 0.731059)
FOXP4-AS1  (Score: 0.731059)
More Information

 

Evidence Support

Strong Evidence:Western Blot//CCK8//qRT-PCR//RIP//Luciferase Report Assay//Transwell Assay
Weak Evidence:

 

Reference

[1] PubMed ID:33416160
Disease Name:Lymphoma, Mantle-Cell
Sample:MCL patients
Dysfunction Pattern:Interaction(miR‑423‑5p/NACC1 )
Validated Method:Western Blot//CCK8//qRT-PCR//RIP//Luciferase Report Assay//Bioinformatics Analysis//Transwell Assay
Description:Our results showed that FOXP4‑AS1 expression was upregulated in MCL patients, and that the high expression of FOXP4‑AS1 was correlated with the unfavorable prognosis of patients. Mechanistically, FOXP4‑AS1 was found to act as a competing endogenous (ce)RNA for miR‑423‑5p to regulate the expression of nucleus accumbens‑associated 1 (NACC1). The negative regulation of FOXP4‑AS1 on miR‑423‑5p compared to that of miR‑423‑5p on NACC1 was determined at the mRNA or protein levels in MCL cells.
Causality:Yes
Causal Description:Functionally, while FOXP4‑AS1 downregulation inhibited proliferation, migration and invasion of MCL cells, FOXP4‑AS1 overexpression had promotive effects on these cellular processes.
Clinical-realted Application:Our results showed that FOXP4‑AS1 expression was upregulated in MCL patients, and that the high expression of FOXP4‑AS1 was correlated with the unfavorable prognosis of patients.